We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
An independent review has cleared Biofrontera of wrongdoing related to its U.S. IPO. Shareholders had accused Biofrontera of acting contrary to its duties when it priced and sold stock in the U.S.....